The Medical Letter on Drugs and Therapeutics
Fiasp - Another Insulin Aspart Formulation for Diabetes
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved Fiasp (Novo Nordisk), a new formulation of insulin aspart, to improve glycemic control in adults with diabetes. Fiasp is described by the manufacturer as faster-acting than conventional insulin aspart (Novolog).

RAPID-ACTING INSULINS — Rapid-acting insulin analogs have a faster onset (10-30 vs 30-60 minutes) and shorter duration of action (3-5 vs 4-12 hours) than regular insulin and are more convenient to use because they can be administered with or just before a meal. In general, the rapid-acting insulins aspart, glulisine (Apidra), and lispro (Humalog) are slightly more effective than regular insulin in decreasing glycated hemoglobin (A1C) concentrations, and cause less hypoglycemia.1 They are all FDA-approved for use by SC injection, continuous SC infusion (insulin pump), or IV infusion in patients ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Fiasp - Another Insulin Aspart Formulation for Diabetes
Article code: 1537c
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian